ProQR Therapeutics CEO Daniel de Boer Acquires 150,000 Shares at $1.59

Daniel de Boer, Chief Executive Officer and Director of ProQR Therapeutics N.V., acquired 150,000 ordinary shares of the company on July 7, 2026, at a price of $1.59 per share. This transaction was reported in a Form 4 filing with the SEC. Following the purchase, de Boer now holds 150,000 shares directly. The filing was signed by Pieter Erik de Ridders as attorney-in-fact on July 8, 2026. This acquisition represents a significant investment by the company's CEO in ProQR Therapeutics, indicating confidence in the company's future prospects at the current share price level.